Results 1 to 10 of about 4,457 (147)
Amrita Journal of Medicine, 2023 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees.
Aishwarya Sudan
doaj +8 more sources
Lecanemab: Appropriate Use Recommendations [PDF]
journal of prevention of Alzheimer's disease, The, 2023 Lecanemab (Leqembi®) is approved in the United States for the treatment of Alzheimer's disease (AD) to be initiated in early AD (mild cognitive impairment [MCI] due to AD or mild AD dementia) with confirmed brain amyloid pathology. Appropriate Use Recommendations (AURs) are intended to help guide the introduction of new therapies into real-world ...
Jeffrey Cummings +2 more
exaly +4 more sources
ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2023 INTRODUCTION Lecanemab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at amyloid plaques.
Lawrence S. Honig +8 more
exaly +2 more sources
Use of lecanemab for the treatment of Alzheimer's disease: A systematic review
Brain and BehaviorPurpose The US Food and Drug Administration authorized lecanemab for the therapeutic use of Alzheimer's disease (AD) in January 2023. To assess the effectiveness and safety of lecanemab in treating AD, we thoroughly examined the studies that are ...
Md Fahad Hossain
exaly +2 more sources
Frontiers in Aging Neuroscience, 2023 ObjectiveWe performed a systematic review and meta-analysis of the cognitive effectiveness and safety of lecanemab on subjects with Alzheimer's disease (AD).MethodsWe screened the literature published before February 2023 in PubMed, Embase, Web of ...
Yue Qiao +3 more
exaly +3 more sources
Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment [PDF]
Alzheimer’s & Dementia: Translational Research & Clinical InterventionsINTRODUCTION Lecanemab, a novel monoclonal antibody targeting both neurotoxic amyloid beta (Aβ) protofibrils and Aβ plaques, substantially reduces markers of amyloid and significantly slows clinical decline on multiple measures of cognition and function ...
Pratik Bhagunde +8 more
doaj +2 more sources
Frontiers in Aging Neuroscience, 2022 Alzheimer’s disease (AD) is the most prevalent form of age-related dementia in the world, and its main pathological features consist of amyloid-β (Aβ) plaque deposits and neurofibrillary tangles formed by hyperphosphorylated tau protein.
Ming-Chao Shi, Fengna Chu
exaly +3 more sources
Journal of Alzheimer's Disease ReportsWe report a 76-year-old patient with mild cognitive impairment and APOE ε3/ε3 genotype who developed a rare pontine hemorrhage following treatment with lecanemab, an anti-amyloid-β monoclonal antibody for Alzheimer's disease.
Lanqiu Yao, Yongan Sun, Qing Peng
exaly +2 more sources
Post-marketing safety of lecanemab: a real-world study based on FAERS database, multicenter cohort and network pharmacology [PDF]
Frontiers in PsychiatryIntroductionLecanemab is a monoclonal antibody targeting amyloid-beta (Aβ) approved for treating Alzheimer’s disease (AD) with mild cognitive impairment or mild dementia. Continuous monitoring of its real-world safety profile remains essential.
Xiaoxuan Xing +13 more
doaj +2 more sources
Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance study [PDF]
Therapeutic Advances in Drug SafetyBackground: Anti-β-amyloid monoclonal antibodies provide a disease-modifying treatment approach for Alzheimer’s disease, but post-marketing safety concerns remain, particularly amyloid-related imaging abnormalities (ARIA).
Wei-Yang Xue +6 more
doaj +2 more sources